通用名称:重组新型冠状病毒融合蛋白疫苗(CHO细胞) 商品名:丽康® 英文名:Recombinant SARS-CoV-2 Fusion Protein Vaccine(CHO Cell) 【成份】本品系由重组CHO细胞(中国仓鼠卵巢细胞)表达的重组新型冠状病毒融合蛋白经精制纯化,加入氢氧化铝佐剂制成。本品不含防腐剂、抗生素。 【接种对象】本品适用于18周岁及以上人群...
（健康时报 任璇）9月3日，丽珠医药集团发布公告称，其与中国科学院生物物理研究所合作研发的重组新型冠状病毒融合蛋白疫苗（V-01）被药监局纳入新型冠状病毒防疫序贯加强免疫紧急使用。据悉，V-01自2020年7月开始立项研发，于2021 年年初获中国国家药品监督管理局批准进行临床试验，适应证为预防新型冠状病毒感染所致疾病...
V-01 is a fusion recombinant protein vaccine with the receptor-binding domain (RBD) as the antigen. RBD is the most critical part of the virus spike protein binding with human cellular ACE2 receptors. The binding process grants the virus access to the host's cells and leads to infection. ...
[2] Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine;NEJM [3] 针对新冠突变病毒,灭活疫苗中和效力最新结果发布;药明康德
preliminarily evaluate the potential of heterologous boosting, we conducted two pilot studies to evaluate the safety and immunogenicity of the V-01 or a bivalent V-01D-351 (targeting Delta and Beta strain) booster after 5–7 months of the primary series of inactivated COVID-9 vaccine (ICV). ...
A successful HIV vaccine eliciting broadly neutralizing antibodies (bnAbs) must overcome the hurdle of being able to activate naive precursor B cells encoding features within their germline B cell receptors (BCR) that allow recognition of broadly neutral
Yan Zhang, Wu-Xiang Guan & Xiong Yu (2022) Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial, Emerging Microbes & Infections, DOI: 10.1080/22221751.2022.2088406...
Yan Zhang, Wu-Xiang Guan & Xiong Yu (2022) Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial, Emerging Microbes & Infections, DOI: 10.1080/22221751.2022.2088406...
https://www.bloomberg.com/news/articles/2021-04-27/russia-protests-after-brazil-rejects-use-of-sputnik-v-vaccine 本期编辑:Henry,微信号healsan。 解析团队简介:Hanson临床科研团队,由6位在美国的医生及医学科学家组成,目前在美国主要从事新药研发和临...
会议名称: AIDS Vaccine 2010 会议时间: 2010/10/01 收藏 引用 批量引用 报错 分享 全部来源 求助全文 ResearchGate 相似文献Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 The structure of VRC01 in complex with the HIV-1 gp120 core reveals that this broadly ...